Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The newly titled Nurse Practitioner Perspective rolls out this month, keeping pace with an educational shift in the nursing field.
The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will flow toward reprints.